{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:33:23Z","timestamp":1794047603852,"version":"4.8.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vaccine.2023.04.028","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T15:38:41Z","timestamp":1681918721000},"page":"3224-3232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2823-0847","authenticated-orcid":false,"given":"Matthias","family":"Girndt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Houser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Manllo-Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9923-0572","authenticated-orcid":false,"given":"John E.","family":"Ervin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5840-9795","authenticated-orcid":false,"given":"Chaim","family":"Charytan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Symonian-Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Lehrner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Linfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Shemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Michelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4904-6013","authenticated-orcid":false,"given":"Robert S.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.04.028_b0005","unstructured":"Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50(RR-5): 1\u201343."},{"key":"10.1016\/j.vaccine.2023.04.028_b0010","doi-asserted-by":"crossref","unstructured":"Previsani N, Lavanchy D, Zuckerman AJ. Hepatitis B. In: Mushahwar IK, ed. Viral hepatitis: molecular biology, diagnosis, epidemiology and control. Amsterdam: Elsevir; 2004, p. 31-98.","DOI":"10.1016\/S0168-7069(03)10002-X"},{"issue":"2","key":"10.1016\/j.vaccine.2023.04.028_b0015","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0272-6386(99)70312-4","article-title":"Protective effect of hepatitis B vaccine in chronic hemodialysis patients","volume":"33","author":"Miller","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2023.04.028_b0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0264-410X(99)00179-6","article-title":"Over a decade of experience with a yeast recombinant hepatitis B vaccine","volume":"18","author":"Assad","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.028_b0025","unstructured":"Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55(RR-16): 1\u201333."},{"issue":"11","key":"10.1016\/j.vaccine.2023.04.028_b0030","doi-asserted-by":"crossref","first-page":"e7359","DOI":"10.5812\/hepatmon.7359","article-title":"Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients","volume":"12","author":"Grzegorzewska","year":"2012","journal-title":"Hepat Mon"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.028_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000013548","article-title":"Hepatitis B virus infection in dialysis patients","volume":"20","author":"Fabrizi","year":"2000","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.vaccine.2023.04.028_b0040","first-page":"14","article-title":"Unmet needs and new promises in hepatitis B vaccination for chronic kidney disease patients","volume":"4","author":"Girndt","year":"2010","journal-title":"Eur Nephrol"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.028_b0045","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000168436","article-title":"Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients","volume":"12","author":"Buti","year":"1992","journal-title":"Am J Nephrol"},{"issue":"8413","key":"10.1016\/j.vaccine.2023.04.028_b0050","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(84)92740-5","article-title":"Clinical evaluation of a recombinant hepatitis B vaccine","volume":"2","author":"Jilg","year":"1984","journal-title":"Lancet"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2023.04.028_b0055","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.vaccine.2003.09.001","article-title":"Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers","volume":"22","author":"Floreani","year":"2004","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2023.04.028_b0060","doi-asserted-by":"crossref","first-page":"9618","DOI":"10.1016\/j.vaccine.2011.10.057","article-title":"Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection","volume":"29","author":"Chaves","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.028_b0065","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0041-1345(00)00914-3","article-title":"Factors influencing response to hepatitis B virus vaccination in hemodialysis patients","volume":"32","author":"Sezer","year":"2000","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.vaccine.2023.04.028_b0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000168977","article-title":"Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection","volume":"16","author":"Navarro","year":"1996","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.vaccine.2023.04.028_b0075","unstructured":"Standing Committee on Vaccination at the Robert Koch Institute. Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute \/ Effective: July 2012. Epid Bull 2012; 30: 283\u201302."},{"key":"10.1016\/j.vaccine.2023.04.028_b0080","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1016\/j.vaccine.2013.05.067","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease","volume":"31","author":"Janssen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.028_b0085","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.vaccine.2014.12.060","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus","volume":"33","author":"Janssen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.028_b0090","unstructured":"HEPLISAV-B\u00ae (Hepatitis B vaccine [recombinant], adjuvanted). Prescribing Information. Dynavax Technologies; 2018."},{"key":"10.1016\/j.vaccine.2023.04.028_b0095","unstructured":"Engerix-B\u00ae (Hepatitis B vaccine [recombinant]) Prescribing Information. GlaxoSmithKline; 2012."},{"key":"10.1016\/j.vaccine.2023.04.028_b0100","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"282","key":"10.1016\/j.vaccine.2023.04.028_b0105","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.vaccine.2023.04.028_b0110","unstructured":"SAS Institute Inc. 2015. SAS\/STAT\u00ae 14.1 User\u2019s Guide. Cary, NC: SAS Institute Inc."},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.028_b0115","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/ajkd.2000.19099","article-title":"A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients","volume":"36","author":"Charest","year":"2000","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.028_b0120","first-page":"122","article-title":"Rapid loss of hepatitis B Immunity in hemodialysis patients","volume":"33","author":"Spiegel","year":"2004","journal-title":"Dialysis Transplant"},{"issue":"7","key":"10.1016\/j.vaccine.2023.04.028_b0125","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.ki.5002725","article-title":"A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients","volume":"73","author":"Kong","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.vaccine.2023.04.028_b0130","doi-asserted-by":"crossref","unstructured":"Lacson E, Teng M, Ong, J, Vienneau L, Ofsthun N. Lazarus, J M. Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease. Hemodial Int 2005; 9(4): 367\u201375.","DOI":"10.1111\/j.1492-7535.2005.01155.x"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:27:24Z","timestamp":1759404444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23004206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":26,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0264410X23004206"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}